**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 69519

**Manuscript Type:** CASE REPORT

**Primary hepatic neuroendocrine neoplasm diagnosed by somatostatin receptor scintigraphy: A case report**

Akabane M *et al*. Primary hepatic NEN

Miho Akabane, Yuta Kobayashi, Keiichi Kinowaki, Satoshi Okubo, Junichi Shindoh, Masaji Hashimoto

**Miho Akabane, Yuta Kobayashi, Satoshi Okubo, Junichi Shindoh, Masaji Hashimoto,** Division of Hepatobiliary-Pancreatic Surgery, Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo 105-8470, Japan

**Keiichi Kinowaki,** Department of Diagnostic Pathology, Toranomon Hospital, Tokyo 105-8470, Japan

**Author contributions:** Akabane M wrote the manuscript; Kobayashi Y contributed to the operation and follow-up, the manuscript design and coordination, and helped draft the manuscript; Kinowaki K contributed to pathological diagnosis; and all authors read and approved the final manuscript.

**Corresponding author: Miho Akabane, MD, Doctor,** Division of Hepatobiliary-Pancreatic Surgery, Department of Gastroenterological Surgery, Toranomon Hospital, 2-2-2, toranomon, minato-ku, Tokyo 105-8470, Japan. akabane.miho@gmail.com

**Received:** July 3, 2021

**Revised:** July 15, 2021

**Accepted:** **January 22, 2022**

**Published online:**

**Abstract**

BACKGROUND

Primary hepatic neuroendocrine neoplasm (NEN) is a rare condition, and it is difficult to differentiate between primary and metastatic hepatic NENs. Herein, we report a case of primary hepatic NEN that initially mimicked a hemangioma but showed a gradual increase in size on long-term careful observation.

CASE SUMMARY

A 47-year-old woman was incidentally diagnosed with a 12-mm liver mass, suspected to be a hemangioma. Since then, regular follow-up had been carried out. Ten years later, she was referred to our institute due to the tumor (located in segment 4) having increased to 20 mm. Several imaging studies depicted no apparent extrahepatic lesion. Positron emission tomography (PET)/computed tomography exhibited significant accumulation in the mass lesion, which made us consider the possibility of malignancy. Left hepatectomy was performed. The histopathological diagnosis was neuroendocrine tumor grade 2, with somatostatin receptor 2a/5 positivity. Postoperative somatostatin receptor scintigraphy (SRS) showed no other site, leading to the diagnosis of NEN of primary hepatic origin. The gradual growth of the hepatic NEN over 10 years suggested that it was likely to be a primary liver tumor.

CONCLUSION

In this case, positivity on PET and postoperative SRS may have helped determine whether the tumor was primary or metastatic.

**Key Words:** Hepatic neoplasm; Scintigraphy; Surgery; Positron-emission tomography; Clinical decision-making; Case report

Akabane M, Kobayashi Y, Kinowaki K, Okubo S, Shindoh J, Hashimoto M. Primary hepatic neuroendocrine neoplasm diagnosed by somatostatin receptor scintigraphy: A case report. *World J Clin Cases* 2022; In press

**Core Tip:** The clinical diagnosis of primary hepatic neuroendocrine neoplasm (NEN) remains challenging due to its rarity and difficulty in differentiating between primary and metastatic NENs. We present a case of primary hepatic NEN that presented with exceedingly gradual growth over 10 years, initially mimicking a hemangioma. Close preoperative observation, positron emission tomography findings, and postoperative somatostatin receptor scintigraphy findings greatly contributed to the final diagnosis. This case highlights the importance of close preoperative observations of NENs. In addition, the clinical usefulness of these modalities for correct diagnosis has been suggested, although regular postoperative follow-up is required.

**INTRODUCTION**

Primary hepatic neuroendocrine neoplasm (NEN) is a rare condition with unclear clinical features. Obtaining a preoperative diagnosis of primary hepatic NEN can pose a challenge. In this report, we describe a case of hepatic NEN that initially mimicked hemangioma but gradually increased in size after close observation for 10 years. Immunohistological staining showed that the tumor cells were positive for somatostatin receptor (SSTR) 2a/5. Postoperative somatostatin receptor scintigraphy (SRS) revealed no other significant site, which supported the idea that the tumor was of primary hepatic origin with gradual tumor progression. This case report was written in accordance with the SCARE guidelines[1].

**CASE PRESENTATION**

***Chief complaints***

The patient had no complaints.

***History of present illness***

A 47-year-old Japanese woman underwent abdominal ultrasound for a medical check-up, which revealed a 12-mm hyperechoic hepatic mass in segment 4. Because the mass was suspected to be a hemangioma, the patient regularly underwent follow-up annual ultrasound examinations to assess its size. Ten years later, the mass had increased to 20 mm. The patient was then referred to our institute because the mass was suspected to be malignant.

***History of past illness***

The patient’s past medical history was not significant, except for uterine myomas.

***Personal and family history***

The patient had no remarkable family history. She denied any specific personal history of other diseases.

***Physical examination***

At her first presentation to our clinic, physical examination revealed a soft, flat, and non-tender abdomen.

***Laboratory examinations***

Her laboratory data indicated that her renal and liver functions were normal. The Child-Pugh score was categorized as class A, and the indocyanine green retention at 15 min was 11.3%. The patient was negative for hepatitis B or C infection. The serum tumor markers, carcinoembryonic antigen, carbohydrate antigen 19-9, alpha-fetoprotein, and protein induced by vitamin K antagonist-II, were all within their normal ranges. All electrolytes were within normal limits.

***Imaging examinations***

Contrast-enhanced computed tomography (CT) revealed a 23-mm liver mass in segment 4, adjacent to the hepatic hilum. The mass exhibited a slight ring-like enhancement in the arterial phase. In the portal and delayed phases, the signal intensity of the mass was lower than that of the surrounding liver tissue (Figure 1). Contrast-enhanced magnetic resonance imaging (MRI) demonstrated a low signal on T1-weighted images and an intermediate signal on T2-weighted images. In the early phase, peripheral enhancement with a low signal was observed inside the mass. Diffusion-weighted images showed a significantly high signal, and the apparent diffusion coefficient (ADC) map demonstrated a low signal. A decreased uptake of gadoxetate sodium was also observed. Positron emission tomography (PET)/CT showed significant accumulation, with a maximum standardized uptake value of 10.1 at the mass. No other abnormal accumulations were observed. Esophagogastroduodenoscopy and colonoscopy revealed no malignant lesions.

**FINAL DIAGNOSIS**

Considering these preoperative imaging studies, malignancy was considered as a differential diagnosis.

**TREATMENT**

Surgical resection was planned as a treatment option. Intraoperatively, we found no ascites, dissemination, or distant metastasis. Although intraoperative ultrasound demonstrated an apparent capsule around the mass in segment 4, the mass was located just on the hilar plate and was stiffly attached to Glisson’s capsule. Therefore, a left hepatectomy was performed to obtain a surgical margin. The postoperative clinical course was unremarkable, and the patient was discharged on postoperative day 14.

**OUTCOME AND FOLLOW-UP**

Gross examination revealed a 2.5 cm × 2.0 cm × 3.0 cm yellowish-white mass with hemorrhage (Figure 2). Histologically, atypical cells with small round nuclei and eosinophilic cytoplasms were arranged in an alveolar, reticular, or trabecular pattern. The cells were characterized by nuclear division, with 2 per 10 high-power fields. Immunohistological staining showed that the tumor cells were positive for chromogranin A/synaptophysin and negative for CD56t. The Ki-67 labeling index was found to be 7%. Thus, a diagnosis of hepatic NEN (grade 2) was made. With respect to SSTR, the scores were 3 for SSTR2a and 2 for SSTR5 (Figure 3). SRS performed in the outpatient clinic identified no other significant accumulation, which cast doubt on the possible existence of primary sites other than the liver. Taking these findings into account, we concluded that the tumor originated in the liver; however, continuous follow-up is essential to completely rule out the possible existence of other primary sites or to identify the appearance of new hepatic lesions in the future. Regular follow-up with imaging studies has been performed since the operation, considering possible recurrence. At the 1-year follow-up, the patient was in good health and free from recurrence.

**DISCUSSION**

NEN is a primary malignant tumor arising from neuroendocrine cells throughout the body. The most common primary sites of NEN are the gastrointestinal tract (67.5%) and the lung/bronchus (25.3%)[2]. Within the gastrointestinal tract, the small intestine (25.3%), rectum (27.4%), and stomach (8.7%) are the most commonly involved organs[2]. Primary hepatic NEN is extremely rare (0.4%)[2] and has no specific imaging findings or biomarkers. Thus, the diagnosis of hepatic NEN is generally difficult. The fact that the liver is frequently the metastatic site of NEN makes this diagnosis even more challenging. Furthermore, early diagnosis is often difficult because patients may have nonspecific symptoms or be asymptomatic, and the growth of NEN is generally slow. In the present case, the doubling time of the mass was calculated to be 46.4 mo, and such a gradual increase might have caused a delay in diagnosis. To the best of our knowledge, the longest observation period before surgery of a hepatic NEN in previous reports was 26 years[3].

Regarding imaging modalities for the diagnosis of primary hepatic NEN, contrast-enhanced CT is often nonspecific because it shows the contrast effect in the arterial phase and washout in the portal phase, which is similar to the classic contrast pattern of hepatocellular carcinoma[4,5]. MRI can depict a low signal on ADC maps/T1-weighted images and a high signal on T2-weighted images[4]. The detection rate of NENs on PET/CT is 25%-73%, which is not very high and may be explained by the fact that NENs have relatively low tumor growth activity compared to carcinomas[6]. However, PET has been reported to be useful in the search for metastasis and the diagnosis of recurrence in patients with high-grade tumors, such as those with abnormal accumulation in the primary lesion[7]. Thus, PET/CT may be useful for differentiating metastatic NENs in the liver. In the present case, peripheral enhancement on CT and MRI and high accumulation on PET/CT also raised the possibility of intrahepatic cholangiocarcinoma with marginal vascular regeneration around the tumor. However, the extremely slow increase in tumor rate made us doubtful of the possibility of cholangiocarcinoma. The present case is noteworthy in that primary hepatic NEN exhibited significant accumulation on PET/CT. To the best of our knowledge, there are no reports showing accumulation at the site of primary hepatic NEN on PET/CT.

Although no clear clinical guidelines have been established for the treatment of primary hepatic NEN, surgical resection remains the basic treatment when feasible[8]. Knox *et al*[9] reported a 5-year postoperative survival rate of 74%-78%, 10-year survival rate of 68%, and recurrence rate of 18%. Although it is often difficult to determine whether NEN is a primary or metastatic lesion preoperatively, there are reports of improved prognosis after tumor reduction surgery even in unresectable or recurrent cases, regardless of whether the tumor is primary or metastatic[10]. Therefore, aggressive surgical resection should always be considered.

Tumors of neuroendocrine origin usually have cell surface receptors with an affinity for somatostatin[11]. SRS is an imaging technique in which gamma-ray emitting radionuclides are labeled on octreotide, which shows an affinity for SSTR expressed on the cell membrane of lesions. Thus, SSTR is expressed in lesions with accumulation on SRS. SSTR has five subtypes, and subtypes 2a and 5 are characteristic of NEN. Volante *et al*[12] defined scores of 2 (membranous reactivity in less than 50% of tumor cells) and 3 (circumferential membranous reactivity in more than 50% of tumor cells) as positive. Hasegawa *et al*[13], who analyzed 16 cases of NEN, reported that the concordance rate between accumulation in a lesion on SRS and pathological SSTR2a expression was 93.8%.

SRS has been reported to have an 89% sensitivity to NEN[14]. However, there are some reports of high accumulation in meningiomas and small cell lung cancer[15], as well as accumulation in non-tumorous conditions including pneumonia, surgical wounds, and the breast[16]. When SRS is performed to investigate the possibility that the primary tumor is located in another organ, as in this case, the interpretation of whether the site of accumulation is the primary site or a false positive should be carefully made in consideration of the other imaging modalities.

In the present case, SRS was performed to identify the presence of a primary site in another organ after histological diagnosis. Scigliano *et al*[17] reported high sensitivity, specificity, and accuracy (89%, 94%, and 91%, respectively) for SRS as a detection method for recurrence. Considering the gradual clinical course and postoperative investigation for another primary site, we thought that the hepatic tumor was most likely to be of primary hepatic origin. In this case, SRS revealed no possible primary or metastatic sites in other organs, and recurrence could be detected by comparative appraisal with the present results of SRS in the future. Therefore, continuous follow-up and preoperative observation are essential. Several reports[18,19] on the usefulness of SRS as a preoperative staging assessment for pancreatic and gastrointestinal NENs have been reported. However, to the best of our knowledge, SRS has not reportedly been performed in a patient with suspected primary hepatic NEN to postoperatively evaluate the possible existence of other primary lesions.

**CONCLUSION**

We observed a long course of gradual tumor growth of hepatic NEN, considered the primary origin, for 10 years. Close preoperative observations, including PET/CT studies, enabled surgical decision-making and curative resection. Postoperative SRS after histological studies may be beneficial in making a final diagnosis.

**REFERENCES**

1 **Agha RA**, Fowler AJ, Saeta A, Barai I, Rajmohan S, Orgill DP; SCARE Group. The SCARE Statement: Consensus-based surgical case report guidelines. *Int J Surg* 2016; **34**: 180-186 [PMID: 27613565 DOI: 10.1016/j.ijsu.2016.08.014]

2 **Modlin IM**, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer* 2003; **97**: 934-959 [PMID: 12569593 DOI: 10.1002/cncr.11105]

3 **Meng XF**, Pan YW, Wang ZB, Duan WD. Primary hepatic neuroendocrine tumor case with a preoperative course of 26 years: A case report and literature review. *World J Gastroenterol* 2018; **24**: 2640-2646 [PMID: 29962820 DOI: 10.3748/wjg.v24.i24.2640]

4 **Wang LX**, Liu K, Lin GW, Jiang T. Primary hepatic neuroendocrine tumors: comparing CT and MRI features with pathology. *Cancer Imaging* 2015; **15**: 13 [PMID: 26272674 DOI: 10.1186/s40644-015-0046-0]

5 **Li R**, Tang CL, Yang D, Zhang XH, Cai P, Ma KS, Guo DY, Ding SY. Primary hepatic neuroendocrine tumors: clinical characteristics and imaging features on contrast-enhanced ultrasound and computed tomography. *Abdom Radiol (NY)* 2016; **41**: 1767-1775 [PMID: 27156080 DOI: 10.1007/s00261-016-0770-3]

6 **Modlin IM**, Latich I, Zikusoka M, Kidd M, Eick G, Chan AK. Gastrointestinal carcinoids: the evolution of diagnostic strategies. *J Clin Gastroenterol* 2006; **40**: 572-582 [PMID: 16917396 DOI: 10.1097/00004836-200608000-00003]

7 **Carideo L**, Prosperi D, Panzuto F, Magi L, Pratesi MS, Rinzivillo M, Annibale B, Signore A. Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review. *J Clin Med* 2019; **8** [PMID: 31337043 DOI: 10.3390/jcm8071032]

8 **Foster DS**, Jensen R, Norton JA. Management of Liver Neuroendocrine Tumors in 2018. *JAMA Oncol* 2018; **4**: 1605-1606 [PMID: 30178021 DOI: 10.1001/jamaoncol.2018.3035]

9 **Knox CD**, Anderson CD, Lamps LW, Adkins RB, Pinson CW. Long-term survival after resection for primary hepatic carcinoid tumor. *Ann Surg Oncol* 2003; **10**: 1171-1175 [PMID: 14654473 DOI: 10.1245/aso.2003.04.533]

10 **Saxena A**, Chua TC, Sarkar A, Chu F, Liauw W, Zhao J, Morris DL. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. *Surgery* 2011; **149**: 209-220 [PMID: 20674950 DOI: 10.1016/j.surg.2010.06.008]

11 **Kumbasar B**, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL. Imaging of neuroendocrine tumors: accuracy of helical CT *vs* SRS. *Abdom Imaging* 2004; **29**: 696-702 [PMID: 15162235 DOI: 10.1007/s00261-003-0162-3]

12 **Volante M**, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. *Mod Pathol* 2007; **20**: 1172-1182 [PMID: 17873898 DOI: 10.1038/modpathol.3800954]

13 **Hasegawa S**, Kobayashi N, Tokuhisa M, Goto A, Takano S, Takada Y, Kaneta T, Mori R, Matsuyama R, Endo I, Yamanaka S, Nakajima A, Inoue T, Ichikawa Y. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors. *Digestion* 2017; **96**: 13-20 [PMID: 28609761 DOI: 10.1159/000470838]

14 **Binderup T**, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, Højgaard L, Kjaer A. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. *J Nucl Med* 2010; **51**: 704-712 [PMID: 20395333 DOI: 10.2967/jnumed.109.069765]

15 **Kwekkeboom DJ**, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. *Neuroendocrinology* 2009; **90**: 184-189 [PMID: 19713709 DOI: 10.1159/000225946]

16 **Gibril F**, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, Doppman JL, Jensen RT. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. *J Nucl Med* 1999; **40**: 539-553 [PMID: 10210211]

17 **Scigliano S**, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, Vullierme MP, Couvelard A, Belghiti J, Ruszniewski P, Le Guludec D. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. *Endocr Relat Cancer* 2009; **16**: 977-990 [PMID: 19470616 DOI: 10.1677/ERC-08-0247]

18 **Kolasińska-Ćwikła AD**, Konsek SJ, Buscombe JR, Maciejkiewicz K, Cichocki A, Roszkowska-Purska K, Sawicki Ł, Tenderenda M, Cwikla JB. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs). *Nucl Med Rev Cent East Eur* 2019; **22**: 1-7 [PMID: 30276787 DOI: 10.5603/NMR.a2018.0032]

19 **Savelli G**, Lucignani G, Seregni E, Marchianò A, Serafini G, Aliberti G, Villano C, Maccauro M, Bombardieri E. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. *Nucl Med Commun* 2004; **25**: 445-449 [PMID: 15100502 DOI: 10.1097/00006231-200405000-00004]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 3, 2021

**First decision:** July 14, 2021

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Ergun Y, Jensen RT **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:**


**Figure Legends**



**Figure 1 Abdominal** **computed tomography.** A: Peripheral contrast enhancement was observed in the atrial phase (arrow); B: In the delayed phase, the contrast of the mass appeared lower than the surrounding liver tissue (arrow); C: The decreased uptake of Gadoxetate sodium was found (arrow); D: Positron emission tomography/computed tomography showed significant accumulation at the mass (arrow).



**Figure 2 Macroscopic findings of the excised specimen.** The specimen was a 2.5 cm × 2.0 cm × 3.0 cm yellowish-white mass with hemorrhage.



**Figure 3 Microscopic findings of the tumor**. A: Atypical cells with small round nuclei and eosinophilic cytoplasm were arranged in an alveolar, reticular, or trabecular pattern. (Hematoxylin and eosin staining results; × 200); B: The tumor cells were positive for Chromogranin A (× 200); C: They were positive for Synaptophysin (× 200); D: They were positive for somatostatin receptor (SSTR)2 (× 200); E: They were positive for SSTR5 (× 400).